[Sibutramine--antidepressive agent tested against obesity]

Area of Science:

• Metabolic disorders
• Pharmacological interventions
• Obesity management

Background:

• Obesity is a complex metabolic disorder requiring effective long-term management strategies.
• Pharmacological interventions combined with lifestyle changes are crucial for sustained weight loss.

Purpose of the Study:

• To evaluate the efficacy and sustainability of sibutramine combined with a calorie deficit for weight loss in obese patients.
• To assess the long-term effects of sibutramine on weight regain and metabolic parameters.

Main Methods:

• A six-month weight loss phase using sibutramine (10 mg/day) and a 600 kcal/day deficit in 605 obese patients.
• Randomization of 467 patients with >5% weight loss to sibutramine or placebo for an additional 18 months.
• Monitoring of weight changes, lipid profiles (VLDL, HDL), and blood pressure.

Main Results:

• Initial weight loss averaged -11.3 kg.
• The placebo group regained weight (-4.7 kg from baseline at 2 years), while the sibutramine group maintained weight loss (-10.2 kg from baseline).
• Significant improvements in VLDL and HDL levels were observed; 3% of patients were withdrawn due to increased blood pressure.

Conclusions:

• An individualized management program combining sibutramine and calorie restriction achieves significant and sustained weight loss in a majority of obese patients.
• Sibutramine treatment is effective in preventing weight regain and improving metabolic markers in obese individuals.
• The treatment is generally well-tolerated, with a small percentage of patients experiencing elevated blood pressure.